DEF: BioAtla Seeks Shareholder Approval for Capital Raise, Reverse Stock Split

BioAtla, Inc. calls a Special Meeting to vote on issuing new shares for capital and a reverse stock split to maintain its Nasdaq listing.

Summary

• BioAtla, Inc. is holding a Special Meeting of Stockholders on December 30, 2025, to vote on three key proposals.
• The first proposal seeks approval for the potential issuance of 20% or more of its common stock (exceeding 11,752,538 shares or 19.99% of outstanding shares as of November 20, 2025) under Pre-Paid Advance Agreements (PPAs) and a Standby Equity Purchase Agreement (SEPA) with Yorkville and Anson Funds.
• This stock issuance is crucial for providing a reliable source of capital for working capital and general corporate purposes.
• The second proposal requests approval for an amendment to the company's charter to effect a reverse stock split at a ratio of 1-for-5 to 1-for-20, at the board's discretion, anytime before June 30, 2026.
• The primary goal of the reverse stock split is to increase the per-share market price of the common stock to regain and maintain compliance with Nasdaq's $1.00 Minimum Bid Price Requirement and potentially the Minimum Stockholders Equity Requirement, avoiding delisting.
• The third proposal authorizes an adjournment of the Special Meeting, if necessary, to solicit additional proxies for the first two proposals.
• The board of directors unanimously recommends voting FOR all three proposals.

Sentiment

Score: 4

Explanation: The company is addressing critical issues (Nasdaq non-compliance, capital needs) with concrete proposals. While these actions are necessary and positive in intent, the underlying situation requiring them (low stock price, need for dilutive financing) reflects a challenging position. The proposals carry significant risks, including potential for further dilution and uncertainty regarding long-term effectiveness.

Positives

• The Agreements (PPAs and SEPA) provide a reliable source of capital for working capital and general corporate purposes, potentially up to $15.0 million from Yorkville under the SEPA and a $7.5 million pre-paid advance under the PPA.
• Maintaining the Nasdaq listing offers numerous benefits, including improved access to financing, furtherance of business strategy, and increased investor and business partner interest.
• A successful reverse stock split could increase the per-share market price, potentially improving trading liquidity and attracting a broader range of institutional investors who may be restricted from investing in low-priced stocks.

Negatives

• The company is currently not in compliance with Nasdaq Listing Rule 5450(a)(1) (Minimum Bid Price Requirement) and Nasdaq Listing Rule 5450(b)(1)(A) (Minimum Stockholders Equity Requirement).
• Failure to approve the Stock Issuance Proposal would limit capital access under the Agreements and could require the company to repay outstanding Pre-Paid Advances in cash, plus a 10% premium, impairing working capital and funding for operations and clinical investment.
• Failure to approve the Reverse Stock Split Proposal could lead to delisting from Nasdaq, impeding stock liquidity, limiting business plan execution, and potentially causing loss of business opportunities or hindering product development.
• The issuance of shares under the Agreements will dilute existing stockholders' proportionate ownership, and the exact magnitude of this dilutive effect cannot be conclusively determined but may be material.

Risks

• The Reverse Stock Split may not increase the price of the common stock over the long-term, and there is no assurance it will achieve compliance or prevent future delisting.
• If the company falls out of compliance with the Minimum Bid Price Requirement within one year of a reverse stock split, it will be immediately subject to delisting without another 180-day compliance period.
• The Reverse Stock Split may decrease the liquidity of the common stock due to a reduced number of outstanding shares and potentially fewer market makers.
• The Reverse Stock Split may result in some stockholders owning 'odd lots' (less than 100 shares), which can be more difficult to sell or incur higher transaction costs per share.
• The Reverse Stock Split may lead to a decrease in the company's overall market capitalization if the per-share price does not increase proportionally.
• The increase in authorized but unissued shares post-reverse split could lead to greater dilution for existing stockholders if the board authorizes additional share issuances in the future.

Future Outlook

The company aims to secure a reliable source of capital through the proposed stock issuance to fund working capital, general corporate purposes, capital expenditures, operating expenses, and clinical investments. It also seeks to regain and sustain compliance with Nasdaq's Minimum Bid Price Requirement and Minimum Stockholders Equity Requirement by February 2, 2026, through a reverse stock split, thereby maintaining its listing on The Nasdaq Capital Market and improving stock liquidity and marketability.

Management Comments

• Our board of directors has determined that the Agreements are in the best interests of us and our stockholders because the ability to issue shares of our Common Stock in excess of the Exchange Cap provides us with a reliable source of capital for working capital and general corporate purposes.
• The primary goal of the Reverse Stock Split Proposal is to increase the per share market price of our Common Stock and trade above the $1.00 minimum threshold in the long term.
• Maintaining our Nasdaq listing as a publicly listed company has numerous benefits to the Company, including, among others, benefits relating to our ability to procure more financing for ongoing operations, our ability to further our business strategy and our ability to attract more investor and business partner interest.
• Our board of directors unanimously recommends that BioAtla stockholders vote FOR the Stock Issuance Proposal, FOR the Reverse Stock Split Proposal, and FOR the Adjournment Proposal.

Industry Context

The need for a reverse stock split to maintain Nasdaq listing is a common occurrence for small-cap biotechnology companies, particularly those in clinical development stages, which often experience share price volatility and may trade below minimum bid requirements. Securing equity financing through agreements like SEPAs and PPAs is also a standard mechanism for such companies to fund their extensive research and development pipelines, given the high capital requirements and long lead times to market for drug candidates.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution from the stock issuance if approved. Will own fewer shares after a reverse stock split, though their percentage ownership will remain largely the same (except for fractional shares). May receive cash in lieu of fractional shares. Face risks of delisting if proposals fail or are ineffective. Potential for increased stock price and liquidity if reverse split is successful.
• Employees (holding equity awards): Equity awards (options, RSUs) and their exercise prices will be proportionally adjusted to maintain economic value post-reverse stock split. The number of shares available for future grants under equity plans will also decrease proportionally.
• Investors (Yorkville, Anson Funds): Will provide capital to the company through the PPAs and SEPA, potentially converting advances into common stock. Yorkville is prohibited from short sales of common stock during the SEPA term.

Next Steps

• Hold a Special Meeting of Stockholders on December 30, 2025, to vote on the proposed stock issuance, reverse stock split, and meeting adjournment.
• If approved, the board of directors will determine the exact ratio (1-for-5 to 1-for-20) and timing for implementing the reverse stock split, which must occur by June 30, 2026.
• The company must demonstrate compliance with the Nasdaq Minimum Stockholders Equity Requirement by December 31, 2025.
• The company must demonstrate compliance with the Nasdaq Minimum Bid Price Requirement by February 2, 2026.
• Voting results will be announced at the Special Meeting and disclosed in a Current Report on Form 8-K within four business days after the meeting.

Key Dates

Recommendation

The company is at a critical juncture, addressing significant challenges related to its Nasdaq listing and capital needs. While the proposed actions (stock issuance and reverse stock split) are necessary defensive measures to ensure continued operations and market presence, they also introduce risks such as dilution and uncertainty regarding long-term stock performance. A 'hold' recommendation is appropriate for existing investors to observe the outcome of these proposals and their subsequent impact on the company's financial health and market position. New investors should exercise caution due to the inherent risks and the company's current precarious situation.

Keywords

BioAtla, Nasdaq, reverse stock split, capital raise, equity financing, proxy statement, delisting risk, biotechnology, stock issuance, corporate governance